Global Malaria Diagnostics Market - 2022-2029

Global Malaria Diagnostics Market - 2022-2029

Market Overview

The global malaria diagnostics market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Malaria is a life-threatening parasitic disease spread by the bite of infected anopheles’ mosquitoes. Infected mosquitos carry the plasmodium parasite. Malaria parasites can be identified by looking at a drop of the patient's blood spread out on a microscope slide as a blood smear.

Market Dynamics

The factors expected to influence the global malaria diagnostics market are increasing technological advancements and efficient diagnostics.

The increasing technological developments are expected to drive the market growth in the forecast period

The development of applications and processes to automate malaria diagnosis may overcome this barrier, allowing patients to be treated more quickly. The gold standard for malaria diagnosis is still a microscopic examination of stained blood smears, which allows for the identification of parasite species, quantification of density, and evaluation of treatment efficacy; however, many malaria-endemic areas lack trained personnel to perform microscopy for diagnosis. Rapid diagnostic tests (RDTs) have become more popular due to their ease of use. Microscopy is the gold standard for detecting parasites in blood smears, with an analytical sensitivity roughly tenfold lower than molecular testing under normal conditions. Microscopes have long been used as a diagnostic tool in outpatient clinics for various reasons, including their accessibility. However, the availability and skills of trained microscopists determine the accuracy of such diagnoses. For instance, because it is inexpensive to perform, differentiate malaria species, and quantify parasites, Giemsa microscopy is regarded as the best diagnostic tool for malaria control. Microscopy has become more feasible in remote areas thanks to high-quality light-emitting diode (LED) illumination and solar battery chargers. Microscopy, on the other hand, necessitates well-trained, competent microscopists, the careful maintenance of functional infrastructures, and effective quality control (QC) and quality assurance (QA).

The problems associated with malaria diagnosis is expected to hamper the market growth

The fact that acquired immunity to malaria can result in asymptomatic infections complicates malaria diagnosis. No existing malaria diagnostic test can distinguish malarial illness from parasitemia with an accompanying fever of another cause in asymptomatic (febrile) patients. Many current treatments rely on a presumptive diagnosis of malaria based on clinical signs and symptoms. Because there are no specific features of malaria, there is a lot of overdiagnosis, especially when the disease is seasonal. As a result, better methods for accurately diagnosing malaria are required, particularly in rural areas where microscopy is impractical. Rapid diagnostic tests are being developed, and their relatively high cost could be offset by reducing the waste associated with anti-malarial drugs used to treat non-malarial illnesses.

COVID-19 Impact Analysis

COVID-19 impacted 32 low- and middle-income countries in 2020, and the magnitude of the disruption. People were affected, and these health services were disrupted. Due to this, many diseases such as malaria are not being tested, diagnosed, or treated as widely as they should be. The gains made so far are jeopardized for HIV/AIDS, tuberculosis, and malaria. So far, the Global Fund has made significant progress in the fight against these three illnesses. The price of commodities is at an all-time low. Having been pushed to the limit by COVID-19, health systems must be strengthened immediately. To provide life-saving tools like tests, medical oxygen, and vaccines are among the treatments available.

While COVID-19 is less severe in children and pregnant women, excess malaria mortality caused by COVID-19-related disruption of health systems and malaria control programs would disproportionately affect these groups, especially in Sub-Saharan Africa. For the World Health Organization's (WHO) Global Malaria Program, the Malaria Atlas Project recently modeled these potential impacts in Africa. Several scenarios were considered, including ending planned ITN distribution campaigns in 2020, reducing routine ITN distribution, and limiting access to effective antimalarial drugs. In the worst-case scenario, a 75% reduction in ITN distribution combined with a 75% reduction in access to artemisinin combination therapies (ACTs) would result in a 22% increase in malaria cases and a doubling of malaria deaths to 769,000 in a year, 70% of which would be in children under the age of 5.

Segment Analysis

The microscopy segment is expected to dominate the market growth in the forecast period

Since its introduction 100 years ago, microscopy has been the gold standard for malaria diagnosis. It performs well when trained professionals in ideal conditions carry out these tests. Globally, approximately 204 million microscopic malaria tests were conducted in 2017, according to WHO estimates. This method can identify malaria parasites at various stages of life, such as P. falciparum, P. malariae, P. ovale, and P. vivax. Furthermore, the parasite density can be quantified to create appropriate treatment plans. The increased adoption of molecular tests is due to their accuracy in diagnosis. Microscopy has a lot of benefits. It allows the causative organism to be identified and quantified. It's also inexpensive and excellent in the hands of a skilled operator. On the other hand, light microscopy is not a viable option in most parts of Sub-Saharan Africa due to inconsistent electricity and a lack of microscopes.

Malaria microscopy allows for the detection of different malaria-causing parasites (Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, and Plasmodium knowlesi), as well as their various parasite stages, including gametocytes, and the quantification of parasite density to track treatment response. For the investigation of malaria treatment failures, microscopy is the method of choice. For malaria microscopy, Giemsa is the recommended stain, and diagnosis requires examination of both thin and thick films from the same patient. Light microscopy has traditionally served as the gold standard against which other diagnostic methods have been measured.

Geographical Analysis

Middle East and Africa region is expected to hold the largest market share in the global malaria diagnostics market

The increasing prevalence of malaria in this region is expected to drive market growth. For instance, according to the WHO, this region is responsible for 92 percent of global malaria cases and 93 percent of global malaria deaths. These numbers show that malaria is becoming more prevalent in Africa. Furthermore, the growing need for early detection and increased awareness about malaria diagnosis are expected to drive the demand for malaria diagnostics. Moreover, malaria killed an estimated 627,000 people in Sub-Saharan Africa in 2020, the majority of whom were young children. The World Malaria Report for 2021 states that in 87 countries and territories, nearly half of the world's population lives in malaria-prone areas. Malaria is caused 241 million clinical episodes and 627,000 deaths by 2020. In 2020, the WHO African Region accounted for 95% of all deaths.

Competitive Landscape

The global malaria diagnostics market is highly competitive with increasing company mergers, collaborations, and product launches. Some of the key players in the market are Abbott Laboratories, Biomérieux Sa, Bio-Rad Laboratories Inc., and Premier Medical Corporation Ltd, Siemens AG, Olympus Corporation, Access Bio. Inc, Atlas Medical, Meridian Bioscience Inc

Biomérieux SA

Overview: Biomérieux SA is a French multinational biotechnology company headquartered in Marcy-l'Étoile, near Lyon, France. Through an extensive network of distributors, bioMérieux is present in 44 countries and serves more than 160 countries. For private and hospital laboratories, bioMérieux develops and manufactures in vitro diagnostic solutions (systems, reagents, software, and services), primarily for diagnosing infectious diseases.

Product Portfolio: VIKIA Malaria Ag Pf/Pan is a malaria prevention and treatment product. Plasmodium antigen is detected qualitatively in human whole blood specimens using a rapid test. It's a helpful tool for diagnosing malaria and distinguishing Plasmodium falciparum from other, less dangerous malaria infections.

Why Purchase the Report?

visualize the composition of the global malaria diagnostics market segmentation by type and end-user highlighting the key commercial assets and players.

Identify commercial opportunities in global malaria diagnostics market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global malaria diagnostics market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global malaria diagnostics market report would provide an access to an approx. 45+market data table, 40+figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers